Life Sciences

REMS represent big change for industry

Pharma Compliance Alert, September 24, 2008

Risk Evaluation and Mitigation Strategies (REMS) could represent the biggest change to drug regulation in decades. And it raises difficult compliance challenges for the pharmaceutical industry, says Meredith Manning, JD, a partner at Hogan and Hartson, in Washington D.C. during the Regulatory Affairs Professionals Society annual seminar September 14-17 in Boston.

Post a Comment





Please enter your comment below:


Please enter the text below:


Most Popular